Karen M Olsson1, Bernhard Meyer, Jan Hinrichs, Jens Vogel-Claussen, Marius M Hoeper, Serghei Cebotari. 1. Department of Respiratory Medicine, German Center for Lung Research, Hannover Medical School, Institute of Diagnostic and Interventional Radiology, German Center for Lung Research, Hannover Medical School, Department of Cardiothoracic, Vascular and Transplantation Surgery, German Center for Lung Research, Hannover Medical School.
Abstract
BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) results from inadequate recanalization of the pulmonary circulation after pulmonary thromboembolism. Its 2-year prevalence is 1-4% . If untreated, patients with CTEPH have a mean life expectancy of less than three years. Fortunately, a number of effective treatments are now available. METHODS: This review is based on a selective search of PubMed for pertinent articles published from 1980 to 2014. RESULTS: The gold-standard test for the exclusion of CTEPH is perfusion scintigraphy: the predictive value of a negative test is nearly 100% . On the other hand, confirmation of a positive diagnosis for treatment planning requires right-heart catheterization and pulmonary angiography. The treatment of first choice for CTEPH is surgical pulmonary endarterectomy (PEA), with which about 70% of patients can be cured. The perioperative mortality of this procedure in experienced centers is now 2-4% . Thirty to 50% of all patients with CTEPH are considered inoperable; for these patients, and for patients with persistent pulmonary hypertension after PEA, the drug riociguat was introduced in Germany in 2014 (the first drug specifically introduced for the treatment of CTEPH). There is also a new interventional treatment option for inoperable patients-pulmonary balloon angioplasty, which is currently being performed in a small number of centers. CONCLUSION: The timely diagnosis of CTEPH, followed by referral to a specialized center, is now more important than ever, because treatment options are now available for nearly all of the forms in which this disease can manifest itself.
BACKGROUND:Chronic thromboembolic pulmonary hypertension (CTEPH) results from inadequate recanalization of the pulmonary circulation after pulmonary thromboembolism. Its 2-year prevalence is 1-4% . If untreated, patients with CTEPH have a mean life expectancy of less than three years. Fortunately, a number of effective treatments are now available. METHODS: This review is based on a selective search of PubMed for pertinent articles published from 1980 to 2014. RESULTS: The gold-standard test for the exclusion of CTEPH is perfusion scintigraphy: the predictive value of a negative test is nearly 100% . On the other hand, confirmation of a positive diagnosis for treatment planning requires right-heart catheterization and pulmonary angiography. The treatment of first choice for CTEPH is surgical pulmonary endarterectomy (PEA), with which about 70% of patients can be cured. The perioperative mortality of this procedure in experienced centers is now 2-4% . Thirty to 50% of all patients with CTEPH are considered inoperable; for these patients, and for patients with persistent pulmonary hypertension after PEA, the drug riociguat was introduced in Germany in 2014 (the first drug specifically introduced for the treatment of CTEPH). There is also a new interventional treatment option for inoperable patients-pulmonary balloon angioplasty, which is currently being performed in a small number of centers. CONCLUSION: The timely diagnosis of CTEPH, followed by referral to a specialized center, is now more important than ever, because treatment options are now available for nearly all of the forms in which this disease can manifest itself.
Authors: C L Bailey; R N Channick; W R Auger; P F Fedullo; K M Kerr; G L Yung; L J Rubin Journal: Am J Respir Crit Care Med Date: 2000-11 Impact factor: 21.405
Authors: Eckhard Mayer; David Jenkins; Jaroslav Lindner; Andrea D'Armini; Jaap Kloek; Bart Meyns; Lars Bo Ilkjaer; Walter Klepetko; Marion Delcroix; Irene Lang; Joanna Pepke-Zaba; Gerald Simonneau; Philippe Dartevelle Journal: J Thorac Cardiovasc Surg Date: 2011-03 Impact factor: 5.209
Authors: Remedios Otero; Mikel Oribe; Aitor Ballaz; David Jimenez; Fernando Uresandi; Dolores Nauffal; Francisco Conget; Consolación Rodriguez; Teresa Elias; Luis Jara; Aurelio Cayuela; Isabel Blanco; Joan Barberá Journal: Thromb Res Date: 2011-01-17 Impact factor: 3.944
Authors: Sulaiman Surie; Nadine S Gibson; Victor E A Gerdes; Berto J Bouma; Berthe L F van Eck-Smit; Harry R Buller; Paul Bresser Journal: Thromb Res Date: 2010-01-20 Impact factor: 3.944
Authors: H U Kauczor; H C Schwickert; E Mayer; W Kersjes; R Moll; F Schweden Journal: Cardiovasc Intervent Radiol Date: 1994 Jul-Aug Impact factor: 2.740
Authors: Vittorio Pengo; Anthonie W A Lensing; Martin H Prins; Antonio Marchiori; Bruce L Davidson; Francesca Tiozzo; Paolo Albanese; Alessandra Biasiolo; Cinzia Pegoraro; Sabino Iliceto; Paolo Prandoni Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: N Sommer; M Hecker; K Tello; M Richter; C Liebetrau; M A Weigand; W Seeger; A Ghofrani; H Gall Journal: Anaesthesist Date: 2016-08 Impact factor: 1.041
Authors: Marius M Hoeper; Hossein-Ardeschir Ghofrani; Ekkehard Grünig; Hans Klose; Horst Olschewski; Stephan Rosenkranz Journal: Dtsch Arztebl Int Date: 2017-02-03 Impact factor: 5.594
Authors: Sabine K Maschke; Thomas Werncke; Cornelia L A Dewald; Lena S Becker; Timo C Meine; Karen M Olsson; Marius M Hoeper; Frank K Wacker; Bernhard C Meyer; Jan B Hinrichs Journal: Sci Rep Date: 2021-10-08 Impact factor: 4.379